Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery
01:32pm, Friday, 06'th Oct 2023
Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.
Key drug in Sudafed, Dayquil and many other decongestants doesn't relieve congestion: FDA
03:32pm, Tuesday, 12'th Sep 2023
WASHINGTON (AP) — The leading decongestant used by millions of Americans looking for relief from a stuffy nose is no better than a dummy pill, according to government experts who reviewed the latest
International Wide-Moat Stocks On Sale - The September 2023 Heat Map
09:05pm, Thursday, 07'th Sep 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th
Bayer says Parkinson's stem cell therapy improves symptoms in initial trial
02:03am, Monday, 28'th Aug 2023
Bayer said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson's disease symptoms in an early 12-patient trial.
New Strong Sell Stocks for August 25th
08:16am, Friday, 25'th Aug 2023
ALCO, BAYRY and CCBG have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2023.
Bayer: Still A Strong Buy Despite Lowered Guidance
12:06am, Tuesday, 22'nd Aug 2023
Bayer reporting disappointing second quarter results with declining sales and lowered the guidance for fiscal 2023. The company is continuing to struggle and total debt increased again and management
Bayer Aktiengesellschaft (BAYZF) Q2 2023 Earnings Call Transcript
01:23pm, Tuesday, 08'th Aug 2023
Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2023 Earnings Call Transcript August 8, 2023 8:00 AM ET Company Participants Oliver Maier - Head of IR Bill Anderson - CEO Wolfgang Nickl - CFO Rodrigo Santos
Bayer (BAYRY) Q2 Earnings Miss Estimates, '23 Outlook Lowered
12:55pm, Tuesday, 08'th Aug 2023
Bayer (BAYRY) misses earnings and sales estimates in the second quarter of 2023 due to lower volumes and decreased prices for glyphosate-based products. Management lowers its guidance.
Bayer: Phase I trial results from Parkinson's cell therapy positive
02:56am, Wednesday, 28'th Jun 2023
Drugmaker Bayer said on Wednesday that initial testing on humans showed that its experimental stem cell therapy to treat Parkinson's disease was well-tolerated and that transplanted cells survived in
Bayer: Easy Deep Value Pitch
12:48am, Tuesday, 27'th Jun 2023
Bayer reported mixed Q1 2023 results, matching analyst consensus expectations with regard to profitability and earnings, but missing on topline and guidance. Long term, Bayer remains well-positioned f
There's a 'strong desire' in big pharma to continue to acquire, says JPMorgan analyst
07:15am, Friday, 23'rd Jun 2023
Juha Anjala, co-head of EMEA health-care investment banking at JPMorgan, discusses government support for investment in life sciences, as well as innovation in the sector.
Bayer reaches $6.9 mln settlement with New York over Roundup safety claims
11:42am, Thursday, 15'th Jun 2023
Bayer AG agreed on Thursday to pay $6.9 million to settle claims by New York Attorney General Letitia James that it misled consumers by advertising Roundup weedkiller as safe.
Bayer reaches $6.9 million settlement with New York over Roundup weedkiller
11:15am, Thursday, 15'th Jun 2023
Bayer AG has reached a $6.9 million settlement with New York for allegedly making false and misleading claims regarding the safety of Roundup weedkillers, the state's Attorney General Letitia James sa
Perrigo hires Bayer's ex-U.S. head as new CEO
07:51am, Thursday, 08'th Jun 2023
Perrigo Co. Plc PRGO, +0.51% on Thursday named Patrick Lockwood-Taylor as its new president and chief executive officer as of June 30. Lockwood-Taylor previously worked in dual roles at Bayer AG as pr
International Wide-Moat Stocks On Sale - The June 2023 Heat Map
09:51pm, Wednesday, 07'th Jun 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued. We share the heat map of the most investable candida
